ESR1 and breast carcinoma: ,22,31 Previous studies found that increased expression of ERα36 resulted in poor disease–free survival and disease–specific survival in two groups: patients that had ER+ breast cancers and were given TAM and patients that had ER- breast cancers regardless of whether they were given TAM or not.31